Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease
Daniela Berg(Christian-Albrechts-Universität zu Kiel), Werner Poewe(University of Verona), Heike Stockner(Innsbruck Medical University), Stefanie Lerche(German Center for Neurodegenerative Diseases), Christoph Pausch(Saarland University), Karin Srulijes(German Center for Neurodegenerative Diseases), Jana Godau(Hertie Institute for Clinical Brain Research), Johann Willeit(Innsbruck Medical University), Stefan Kiechl(Innsbruck Medical University), Alexandra Gaenslen(German Center for Neurodegenerative Diseases), Thomas Gasser(Hertie Institute for Clinical Brain Research), Inga Liepelt‐Scarfone(German Center for Neurodegenerative Diseases), Stefanie Behnke(University Medical Center), Isabel Wurster(German Center for Neurodegenerative Diseases), Klaus Seppi(Innsbruck Medical University), Klaus Faßbender(Saarland University), Arno Gasperi(Krankenhaus Bruneck), Philipp Mahlknecht(University College London), Heiko Huber(German Center for Neurodegenerative Diseases), Niko R. E. Schneider(Saarland University), Kathrin Brockmann(Oregon Health & Science University)
Cited by 129
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k